Therapeutic drug compositions and implants for delivery of same
AssigneeGlaukos Corporation
InventorsHarold A. Heitzmann, Kenneth M. Curry, David S. Haffner, Timothy P. Murphy
Life of this patent
Estimating the term…
Abstract
Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. In several embodiments, the devices are configured to release a pro-drug form of a drug into a target tissue site, wherein the pro-drug is converted to an active drug that yields a therapeutic effect. The use of the device and pro-drug form advantageously, in several embodiments, provide a stable drug composition that can yield a therapeutic effect over an extended time period.
Claims28
An ocular drug delivery implant comprising:
- an outer shell having a proximal end and a distal end and defining an interior space between the proximal and distal ends;
- at least a first drug positioned within said interior space, said first drug being combined with at least one excipient comprising an antioxidant;
- wherein said outer shell includes at least one rate-limiting element through which said first drug is capable of eluting in a controlled fashion,
- wherein said at least one rate-limiting element is located at either the proximal end or at the distal end of the outer shell,
- wherein upon implantation of said implant in an ocular target region, said first drug elutes out of said implant.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-56. (canceled)
An ocular drug delivery implant comprising:
- an outer shell having a proximal end and a distal end and defining an interior space between the proximal and distal ends;
- at least a first drug positioned within said interior space, said first drug comprising a synthetic prostaglandin or pro-drug thereof and being combined with at least one excipient comprising an antioxidant;
- wherein said outer shell includes at least one rate-limiting element through which said first drug is capable of eluting in a controlled fashion,
- wherein said at least one rate-limiting element is located at either the proximal end or at the distal end of the outer shell,
- wherein upon implantation of said implant in an ocular target region, said first drug elutes out of said implant.
(canceled)
(canceled)
-97. (canceled)
Dependencies are inferred from the claim text.